Humanigen Inc (HGENQ)

[fireopal]

checked in with bankruptcy reviewed website and caught the following:


"... Per its latest SEC filing/presentation, KaloBios projects an NDA submission for benznidazole in the first half of 2018. And I wrote back in August 2016, “I still don’t see an FDA approval for benznidazole until at least mid-2018. And that’s probably optimistic.” It appears that KaloBios projects an FDA approval possibly 6 months later, at the end of 2018, given its projecting timing for the PRV. FWIW, I agree with the anticipated resale value of the PRV, no matter who gets the lion’s share of the money. In February, Sarepta sold its PRV, after the approval of eteplirsen, for $125 million..." (http://bmartinmd.com/2017/02/another-priority-review-voucher-prv-sold-time-125-million/)...";